Format

Send to

Choose Destination
See comment in PubMed Commons below
Viruses. 2010 Jun 25;2(7):1347-66.

Resistance to integrase inhibitors.

Author information

1
Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 37 Convent Drive, Bethesda, MD 20892, USA.

Abstract

Integrase (IN) is a clinically validated target for the treatment of human immunodeficiency virus infections and raltegravir exhibits remarkable clinical activity. The next most advanced IN inhibitor is elvitegravir. However, mutant viruses lead to treatment failure and mutations within the IN coding sequence appear to confer cross-resistance. The characterization of those mutations is critical for the development of second generation IN inhibitors to overcome resistance. This review focuses on IN resistance based on structural and biochemical data, and on the role of the IN flexible loop i.e., between residues G140-G149 in drug action and resistance.

KEYWORDS:

AIDS; Elvitegravir; GSK-1265744; GSK-1349572; HIV-1 integrase; Raltegravir; interfacial inhibitors; resistance

PMID:
20706558
PMCID:
PMC2920056
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for PubMed Central
    Loading ...
    Support Center